A post hoc analysis based on the data from the POPLAR and OAK trials by Gandara et al. initially explored the role of bTMB in the immunotherapy response, and the results showed that higher bTMB was associated with improved OS, PFS and ORR among NSCLC patients receiving atezolizumab monotherapy; moreover, bTMB-low patients could also obtain a long-term survival benefit from PD-1/PD-L1 inhibitor therapy [29]. Here, CD274 is linked to non-small cell lung carcinoma.